In today’s session Novo Nordisk A S (ADR) (NVO) recorded an unusually high (147) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the June, 2017 put, expecting serious NVO decrease. With 147 contracts traded and 2974 open interest for the Jun, 17 contract, it seems this is a quite bearish bet. The option with symbol: NVO170616P00035000 closed last at: $3.8 or 0% . About 2.18M shares traded hands. Novo Nordisk A S (ADR) (NYSE:NVO) has declined 38.35% since April 8, 2016 and is downtrending. It has underperformed by 44.00% the S&P500.
Novo Nordisk A S (ADR) (NYSE:NVO) Ratings Coverage
Out of 13 analysts covering Novo Nordisk (ADR) (NYSE:NVO), 3 rate it a “Buy”, 2 “Sell”, while 8 “Hold”. This means 23% are positive. Novo Nordisk (ADR) has been the topic of 13 analyst reports since August 28, 2015 according to StockzIntelligence Inc. The company was upgraded on Wednesday, August 31 by HSBC. The stock has “Outperform” rating given by BNP Paribas on Tuesday, September 13. The rating was upgraded by Jyske Bank to “Strong Buy” on Monday, October 19. As per Friday, August 28, the company rating was initiated by Leerink Swann. As per Monday, October 31, the company rating was downgraded by DNB Markets. UBS downgraded the stock to “Sell” rating in Monday, February 8 report. The firm has “Neutral” rating by JP Morgan given on Friday, September 9. The stock has “Underperform” rating given by Bank of America on Friday, October 28. The firm has “Conviction Buy” rating by Goldman Sachs given on Monday, February 15. The rating was initiated by Piper Jaffray with “Neutral” on Friday, September 23.
According to Zacks Investment Research, “Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world’s largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.”
Novo Nordisk A/S is a healthcare company. The company has a market cap of $69.83 billion. The Firm is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. It has a 15.65 P/E ratio. The Company’s business divisions include diabetes and obesity care, and biopharmaceuticals.
NVO Company Profile
Novo Nordisk A/S, incorporated on November 28, 1931, is a healthcare company. The Firm is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business divisions include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy.
More news for Novo Nordisk A S (ADR) (NYSE:NVO) were recently published by: Marketwatch.com, which released: “Virtual Stock Exchange” on July 03, 2009. Quotes.Wsj.com‘s article titled: “DOW JONES, A NEWS CORP COMPANY” and published on February 11, 2011 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.